ライフサイエンスコーパス: sulfoximine

1 inhibition by glutamine, AMP, and methionine sulfoximine.

2 ield S,S-dimethyl-N-[(phenylmethoxy)carbonyl]sulfoximine.

3 on of glutamate to glutamine with methionine sulfoximine.

4 sgenic plants were abrogated by l-buthionine sulfoximine.

5 eatment with homocysteic acid and buthionine sulfoximine.

6 cted even after extended incubation with the sulfoximine.

7 , N-acetyl-l-cysteine, or d,l-buthionine-S,R-sulfoximine.

8 spite further depletion of GSH by buthionine sulfoximine.

9 mM) with or without GSH ester or buthionine sulfoximine.

10 ione synthetase inhibitor L-buthionine-(S,R)-sulfoximine.

11 subcutaneous administration of L-buthionine sulfoximine.

12 hibition of GSH synthesis with dl-buthionine sulfoximine.

13 t is inactivated by cystamine and buthionine sulfoximine.

14 e, glycine, phosphinothricin, and methionine sulfoximine.

15 ing effects of GSH depletion with buthionine sulfoximine.

16 of the N-acyl group to give the S-methyl NH sulfoximine.

17 d decarboxylation provided the S-cyclopropyl sulfoximine.

18 inhibition of GSH biosynthesis by buthionine sulfoximine.

19 tamylcysteine synthesis inhibitor buthionine sulfoximine.

20 bition by glutamine, glycine, and methionine sulfoximine.

21 GSH, cystamine, and transition state analog sulfoximines.

22 ribed, and provides a complementary route to sulfoximines.

23 otection, the products are converted into NH-sulfoximines.

24 nd fundamentally new asymmetric synthesis of sulfoximines.

25 of cyclopropenones with weakly nucleophilic sulfoximines.

26 s not been successfully applied to NH-diaryl sulfoximines.

27 ondiimines are aza-analogues of sulfones and sulfoximines.

28 lity and gives several unprecedented N-azine sulfoximines.

29 odobenzene directly converts sulfoxides into sulfoximines.

30 hilic substitution of azine N-oxides with NH-sulfoximines.

31 tions results in the formation of NH-S-alkyl sulfoximines.

32 d cultures of vSMCs with DL-buthionine-(S,R)-sulfoximine (0.1 mM), a depletor of cellular glutathione

33 ing groups including pyrrolidine amide, azo, sulfoximine, 1-pyrazole, and 1,2,3-triazole functionalit

34 on a gram scale allowed using the recovered sulfoximine (+)-1j in an asymmetric synthesis of FXa inh

35 Specifically, 24-(S)-NH phenyl sulfoximine 3a is an extremely potent CYP24 inhibitor (I

36 agine depletion via the ASNS inhibitor amino sulfoximine 5 (AS5) or asparaginase inhibited mouse and

37 ic acid (an inhibitor of GST-Pi), buthionine sulfoximine (a glutathione synthesis inhibitor), MK571 (

38 Treating tolerant mice with buthionine sulfoximine, a gamma-GCS inhibitor, eliminates resistanc

39 In normal islets, methionine sulfoximine, a glutamine synthetase inhibitor, suppresse

40 ement for cellular sensitivity to buthionine sulfoximine, a glutathione synthesis inhibitor.

41 utralizing antibody (Ab) and by L-buthionine-sulfoximine, a GSH-depleting agent.

42 oxicity can be blocked by l-buthionine-(S,R)-sulfoximine, a specific inhibitor of glutamate-cysteine

43 17 in solution containing l-buthionine-(S,R)-sulfoximine, a specific inhibitor of GSH biosynthesis.

44 glutamine synthetase inhibitor l-methionine sulfoximine abolished the ability of asparagine, arginin

45 Alternatively, sulfoximine alkylation with dibromoethane followed by ac

46 e glutathione synthesis inhibitor buthionine sulfoximine all cause oxidative injury to immature neuro

47 We found that this sulfoximine also inhibited AS-B, effectively irreversibl

48 amma-glutamylcysteine synthetase, buthionine sulfoximine, also decreased intracellular glutathione le

49 of NFI activity in vivo, we used buthionine sulfoximine, an agent that inhibits GSH synthesis, and N

50 okine production was inhibited by buthionine sulfoximine, an inhibitor of GCL.

51 Treatment of MCF-7 lines with buthionine sulfoximine, an inhibitor of glutathione synthesis, norm

52 esistant to the toxicity of buthionine-(S,R)-sulfoximine, an inhibitor of glutathione synthesis, than

53 , dogs were treated for 48 h with buthionine sulfoximine, an inhibitor of glutathione synthesis.

54 Treatment with buthionine sulfoximine, an inhibitor of GSH synthesis, also sensiti

55 A dozen 24-sulfoximine analogues of the hormone 1alpha,25-dihydroxy

56 B3 cells pretreated with 10 mM DL-buthionine sulfoximine and 0.5 mM acivicin were used in GSH uptake

57 Hepatocytes were cultured with buthionine sulfoximine and 1,3-bis(chloroethyl)-1-nitrosourea (BCNU

58 thod shows a good scope with a wide-range of sulfoximine and alkynoates and displays regioselectivity

59 increased up to 80% with combined buthionine sulfoximine and arsenic treatments, suggesting the enhan

60 Both buthionine sulfoximine and BCNU inhibited the induction of iNOS mRN

61 As with other GCL, buthionine sulfoximine and cystamine inactivate the Arabidopsis enz

62 kout/muscle) and pharmacological (methionine sulfoximine and dexamethasone) approaches to modulate GS

63 athione by treatment with L-buthionine-(S,R) sulfoximine and diethyl maleate, revealed no changes in

64 the glutathione-depleting agents buthionine sulfoximine and diethylmaleate were more potent in deple

65 ificantly reduced by the toxins L-methionine sulfoximine and fluoroacetate, which reduce glutamine co

66 e using the glutamate analogues l-methionine sulfoximine and l-methionine sulfone as substrates, with

67 5 +/- 43 and 610 +/- 23 s-1 for l-methionine sulfoximine and l-methionine sulfone, respectively.

68 Among them, sulfoximine and pyridinyl derivatives 24 and 29 possesse

69 nthetic methodologies for constructing vinyl sulfoximine and vinyl sulfonimidamide architectures that

70 drogenative Chan-Lam coupling of free diaryl sulfoximines and arylboronic acids is described.

71 imines are reported and compared to those of sulfoximines and other more traditional functional group

72 thods that produce enantiomerically enriched sulfoximines and sulfinimines are far less well develope

73 lfenimines to form enantiomerically enriched sulfoximines and sulfinimines respectively, on preparati

74 Sulfoximines and sulfonimidamides are promising compound

75 olute configuration of enantioenriched vinyl sulfoximines and sulfonimidamides by comparing experimen

76 trogen nucleophiles enables the synthesis of sulfoximines and sulfonimidamides in a reaction time of

77 for the synthesis of the most diverse set of sulfoximines and sulfonimidamides yet described.

78 sely, the S(VI) aza-isosteres thereof, vinyl sulfoximines and sulfonimidamides, are far less studied

79 ms are replaced by imidic nitrogens, such as sulfoximines and sulfonimidamides, are gaining attractio

80 describe a unified, one-pot approach to both sulfoximines and sulfonimidamides, which exploits the hi

81 onditions for rhodium catalyzed synthesis of sulfoximine (and sulfilimine) carbamates, especially for

82 Oxetane and azetidine heterocyclic, -sulfoximine, and -phosphonate derivatives are prepared,

83 with the GSH synthesis inhibitor buthionine sulfoximine, and aminonicotinamide (6-ANAM), an inhibito

84 tathione-depleting agent, L-buthionine-[S,R]-sulfoximine, and attenuated in cells pretreated with an

85 hylcytosine in cells treated with buthionine sulfoximine, and in mice depleted for the major antioxid

86 Aminotriazole, L-buthionine sulfoximine, and sodium azide partly abrogated the RGC r

87 the substitution pattern in the ligand, the sulfoximine, and the reactive aryl on neutral triarylbis

88 sulfoxides, sulfinamides, N-sulfinyl ureas, sulfoximines, and some related S-chiral derivatives.

89 rogen peroxide concentrations and buthionine sulfoximine- and auranofin-induced inhibition of glutath

90 New sulfoximine- and phenanthrene-based photochemical precur

91 Mechanisms for the formation of the sulfoximine are presented as well as the product charact

92 Given that sulfoximines are a bioactive pharmacophore of ever-incre

93 As sulfoximines are analogues of sulfones where one of the

94 In the sulfilimine series, sulfoximines are generated in up to 98% ee via a kinetic

95 Sulfoximines are increasingly incorporated in agrochemic

96 Sulfoximines are increasingly utilized in pharmaceutical

97 Sulfoximines are of considerable interest for incorporat

98 The BCB sulfoximines are shown to react selectively with cystein

99 hesis of 1,2-benzothiazine derivatives using sulfoximine as a directing group under C-H activation st

100 cysteine synthetase (gammaGCS) by buthionine sulfoximine augmented the increase in islet peroxide and

101 Sulfoximines bearing Boc and Cbz groups are stable to fu

102 Here we report the synthesis of sulfoximine bicyclo[1.1.0] butanes (BCBs) as novel thiol

103 H synthesis in a Glu (10 mM) plus buthionine-sulfoximine (BSO) (0.2 mM)-treated group, indicating tha

104 anced toxicity in the presence of buthionine sulfoximine (BSO) and attenuation of toxicity with exoge

105 on of GSH and Trx metabolism with buthionine sulfoximine (BSO) and auranofin (AUR), respectively, ind

106 used to investigate effects of l-buthionine sulfoximine (BSO) and pyrrolidine dithiocarbamate (PDTC)

107 es have identified nifurtimox and buthionine sulfoximine (BSO) as effective agents in children with n

108 hereas glutathione depletion with buthionine sulfoximine (BSO) augmented them.

109 nontoxic concentration of D,L-buthionine-S,R-sulfoximine (BSO) caused about 80-88% reduction in cellu

110 ressing cells by treatment with l-buthionine sulfoximine (BSO) causes decreased cell viability.

111 h 0.2 mmol/L diamide and 1 mmol/L buthionine sulfoximine (BSO) decreased GSH levels and increased the

112 dl-buthionine-[S, R]-sulfoximine (BSO) decreased intracellular GSH level, but

113 atment of AREc32 cells with l-buthionine-S,R-sulfoximine (BSO) did not influence basal levels of luci

114 d then were treated with DL-buthionine-(S,R)-sulfoximine (BSO) for an additional 24 hours.

115 l-Buthionine-S-sulfoximine (BSO) is a mechanism-based inhibitor of GCL

116 Glutathione (GSH) depletion by buthioninine sulfoximine (BSO) is being explored clinically as a mean

117 h glutathione synthesis inhibitor buthionine sulfoximine (BSO) leads to synergistic cell growth inhib

118 study, we examined the effect of buthionine sulfoximine (BSO) on mutation frequency and the formatio

119 eversible inhibitor of gammaGCS L-buthionine sulfoximine (BSO) reduced intracellular GSH levels in P.

120 Depletion of GSH by buthionine sulfoximine (BSO) restores the sensitivity of resistant

121 eduction of glutathione levels by buthionine sulfoximine (BSO) significantly enhanced the activity of

122 -D-glucose exposure using l-buthionine-[S,R]-sulfoximine (BSO) significantly enhanced the cytotoxic e

123 7, the cells were treated with L-buthionine sulfoximine (BSO) to deplete glutathione stores.

124 increased after treatment with L-buthionine sulfoximine (BSO) to lower GSH levels.

125 ed cytoenhancement, using L-buthionine-[S,R]-sulfoximine (BSO) to reduce cellular glutathione levels

126 ath caused by depletion of GSH by buthionine sulfoximine (BSO) was increased in mE10 and mE27 cells a

127 O(3) alone or in combination with buthionine sulfoximine (BSO) was studied in NB4, U937, Namalwa, and

128 GC-5 cells treated with glutamate/buthionine sulfoximine (BSO) were determined by RGC density analysi

129 eating uninfected astrocytes with buthionine sulfoximine (BSO), a glutathione synthesis inhibitor, or

130 ats were treated with: (1) L-buthionine(S,R)-sulfoximine (BSO), a specific inhibitor of gamma-glutamy

131 Treatment of cells with buthionine sulfoximine (BSO), an enzyme-activated inhibitor of gamm

132 Buthionine sulfoximine (BSO), an inhibitor of glutathione (GSH) syn

133 a glutathione-depleting agent, or buthionine sulfoximine (BSO), an inhibitor of glutathione synthesis

134 Buthionine sulfoximine (BSO), an inhibitor of glutathione synthesis

135 ced hearing loss by using l-buthionine-[S,R]-sulfoximine (BSO), an inhibitor of GSH synthesis, and 2-

136 l-Buthionine-S,R-sulfoximine (BSO), an inhibitor of GSH synthesis, marked

137 L-buthionine-S,R-sulfoximine (BSO), an inhibitor of GSH synthesis, was us

138 iving T cells and is abrogated by buthionine sulfoximine (BSO), an inhibitor of GSH synthesis.

139 when GSH synthesis was blocked by buthionine sulfoximine (BSO), an inhibitor of the enzyme required f

140 d tap water (vehicle) and 30 mM L-buthionine sulfoximine (BSO), an oxidant, with and without 1 mM tem

141 to date are rapidly inhibited by buthionine sulfoximine (BSO), most reports indicate that bacterial

142 s with diethyl maleate (DEM), D,L-buthionine sulfoximine (BSO), or tert-butylhydroquinone (TBH).

143 of glutathione synthesis, l-buthionine-[S,R]-sulfoximine (BSO), sensitized FaDu cells to the cytotoxi

144 ion by 18 hours pretreatment with buthionine sulfoximine (BSO), which depletes GSH by blocking its bi

145 E47 cells against AA toxicity or buthionine sulfoximine (BSO)-dependent toxicity.

146 osed to either L-glutamic acid or buthionine sulfoximine (BSO).

147 y exposing BPAE cells to dl-buthionine-[S,R]-sulfoximine (BSO).

148 igational chemotherapeutic agent buthionione sulfoximine (BSO).

149 ed by treating the cells with buthionine S,R-sulfoximine (BSO); 1-chloro, 2,4-dinitrobenzene (CDNB);

150 ulating redox homeostasis using l-buthionine-sulfoximine (BSO, glutathione synthesis inhibitor) and a

151 inhibitor buthionine sulfoximine (buthionine sulfoximine [BSO], 30 mmol/L) in drinking water for 2 wk

152 sents an appealing approach to access N-aryl sulfoximines, but has not been successfully applied to N

153 he glutathione synthase inhibitor buthionine sulfoximine (buthionine sulfoximine [BSO], 30 mmol/L) in

154 tal-free method for the synthesis of N-azine sulfoximines by the nucleophilic substitution of azine N

155 The inhibition of GS by methionine sulfoximine can be explained by the same mechanism.

156 Both enantiomers of the sulfoximines can be obtained with excellent ee values (u

157 tably we report the preparation of propargyl sulfoximine carbamates to provide an alkyne as a potenti

158 In comparison with analogue Ir/phosphine-sulfoximine catalysts previously reported, the presence

159 his work identifies a family of Ir/phosphite-sulfoximine catalysts that has been successfully used in

160 Combined BaP/DL-buthionine-(S, R)-sulfoximine challenge was cytotoxic to the cells and inh

161 n pharmaceuticals and agrochemicals with all sulfoximine clinical candidates incorporating either an

162 nversely, the GSH-depleting agent buthionine sulfoximine completely abolished the protective effects

163 cess elaboration was blocked by L-buthionine sulfoximine, consistent with mediation by an antioxidant

164 transformations in the laboratory leading to sulfoximine degradations.

165 A sulfoximine-directed C-H activation strategy catalyzed b

166 d development of the first iridium-catalyzed sulfoximine-directed hydrogen isotope exchange (HIE) sys

167 y viable under the influence of methylphenyl sulfoximine directing group constructing three different

168 The reusable sulfoximine directing-group-assisted Ru(II)-catalyzed ch

169 enerators menadione, paraquat, or buthionine sulfoximine down-regulates c-FLIP long (c-FLIP(L)) prote

170 biting glutathione synthesis with buthionine-sulfoximine dramatically increased red blood cell sickli

171 trachlorobiphenyl, dexamethasone, buthionine sulfoximine, ethacrynic acid, or N-acetylcysteine pretre

172 ragine synthesis could be inactivated by the sulfoximine; free enzyme was unaffected even after exten

173 Pretreatment of HeLa cells with buthionine sulfoximine greatly potentiated the inactivation of NFI

174 nd methyllithium afforded replacement of the sulfoximine group by phenyl and methyl, respectively.

175 thiazole incorporating the S-trifluoromethyl sulfoximine group in their core.

176 ion units containing sulfoxide, sulfone, and sulfoximine groups at C4 unveils an enhancement in bindi

177 s was inhibited by treatment with buthionine sulfoximine, GSH levels rapidly declined in E47 cells bu

178 eover, glutathione depletion with buthionine sulfoximine had no effect on MX transport or sensitivity

179 sulfoxamination of 1-naphthalamides with NH-sulfoximines has been developed.

180 cross-coupling between cinnamic acids and NH-sulfoximines has been developed.

181 The interest in fluorinated sulfoximines has rapidly increased over the past twenty

182 x with one of these substrates (l-methionine sulfoximine) has been solved, revealing the mode of its

183 Sulfoximines have been largely disregarded in medicinal

184 In recent years, sulfoximines have received significant attention in both

185 ns of the GSH synthesis inhibitor buthionine sulfoximine in the nucleus accumbens impaired effort-bas

186 d allows the synthesis of substituted cyclic sulfoximines in high yields with complete stereocontrol,

187 ent reductive cleavage affording the free-NH sulfoximines in high yields.

188 lfinimines provides access to complex chiral sulfoximines in only two steps from commercially availab

189 nes, sulfoxides, sulfones, sulfonamides, and sulfoximines, in the hydrogenation of quinolines.

190 esent the specific properties of fluorinated sulfoximines (including important bioactivities) and des

191 We show that nontoxic doses of l-buthionine sulfoximine increase the selectivity of organo-Os comple

192 reased, whereas the Gcl inhibitor buthionine sulfoximine increased DomA toxicity.

193 Pretreatment with L-buthionine sulfoximine increased SFN-induced ARE expression signifi

194 e by treatment of Hepa cells with buthionine sulfoximine increased the inducer potencies of several i

195 etion of intracellular GSH by D,L-buthionine sulfoximine increased the intracellular accumulation of

196 omyocytes, Rac1 activation with l-buthionine sulfoximine increased; Rac1 inhibition with NSC23766 dec

197 utathione) in A(L) cells with buthionine S-R-sulfoximine increases the mutagenic potential of arsenit

198 ione using N-acetylcysteine and L-buthionine-sulfoximine indicate that changes in glutathione levels

199 Neither Gln nor l-methionine sulfoximine-induced ammonium accumulation were effective

200 glutamate-, homocysteine-, and l-buthionine sulfoximine-induced toxicity.

201 Methionine sulfoximine inhibition of glucose stimulated insulin sec

202 e sulfinic acid interaction with AS-B or the sulfoximine interaction with AS-A, only AS-B productivel

203 elanthamidine, by transformation of a cyclic sulfoximine into a pyrroline, is also disclosed.

204 A convenient synthesis of N-protected sulfoximines is achieved, under mild conditions, by rhod

205 dine 2-carboxylates to unusual chiral cyclic sulfoximines is described herein.

206 esis of a variety of chiral sulfilimines and sulfoximines is described.

207 owledge of potential degradation pathways of sulfoximines is vital.

208 have shown that 10 microM L-buthionine-[S,R]-sulfoximine (L-BSO), an inhibitor of gamma-glutamylcyste

209 hione (GSH)-depleting compound, L-buthionine sulfoximine (L-BSO), exhibited enhanced sensitivity to D

210 the GSH synthesis inhibitor L-buthionine-S,R-sulfoximine (L-BSO).

211 bition of glutamine synthetase by methionine sulfoximine led to a substantial reduction in putrescine

212 ctivity by ATG and glutathione by buthionine sulfoximine led to overoxidation of Trx1 and loss of HeL

213 V) fluorides, featuring a dianionic bis-aryl sulfoximine ligand.

214 Depleting the GSH pool using buthionine sulfoximine limits fly survival, thus confirming that en

215 MK571, PSC833, and buthionine sulfoximine markedly increased cellular arsenic accumula

216 vity of glutamine synthetase with methionine-sulfoximine (MSO) and examined ammonia levels, brain wat

217 berculosis, the GS inhibitor L-methionine-SR-sulfoximine (MSO) protected the animals against weight l

218 imately 28 days) microinfusion of methionine sulfoximine (MSO: 0.625 to 2.5 microg/h) unilaterally in

219 mine synthesis in astrocytes with methionine sulfoximine (MSO; 1.5 mM) had no effect on miniature IPS

220 m reporters: nitrogen starvation, methionine sulfoximine (Msx) addition, nitrogen limitation, rapamyc

221 ed forms of methionine, including methionine sulfoximine (MSX) and methionine sulfone (MSO).

222 e glutamine synthetase inhibitor, methionine sulfoximine (MSX), although eliciting the same outcomes

223 ition, we studied the effect of L-methionine sulfoximine (MSX), an inhibitor of NH4+ assimilation by

224 as stabilized by phosphorylated L-methionine sulfoximine (MSX), fixing the enzyme in the transition s

225 tabolite repression-sensitive and methionine sulfoximine (Msx)-responsive) regulatory pathways.

226 r those treated with rapamycin or methionine sulfoximine (Msx).

227 treatment, and strong response to methionine sulfoximine (Msx, a glutamine synthetase inhibitor).

228 ) confirms that BSO is phosphorylated on the sulfoximine nitrogen to generate the inhibitory species

229 cological inhibition of GLUL by l-methionine sulfoximine not only repressed ccRCC lipid deposition an

230 euticals, with the two enantiomers of chiral sulfoximines often having profoundly different binding i

231 ither by the addition of DL-buthionine-(S,R)-sulfoximine or by removal of L-cystine from the culture

232 llular glutathione depletion with buthionine sulfoximine or energy depletion using 2-deoxy-D-glucose/

233 ion of glutathione synthesis with buthionine sulfoximine or inhibition of glutathione reductase activ

234 esolution of the resulting ketones by either sulfoximine or mandelate acetal technology has been appl

235 al inhibition of TOR signaling by methionine sulfoximine or rapamycin also increased CLS.

236 bitor of glutathione synthesis (L-buthionine-sulfoximine) or glutathione reductase (1,3-bis(2-chloroe

237 analogs N-methyl-D-aspartate and methionine sulfoximine, or by hyperbaric oxygen, are prevented by D

238 hibitor of glutathione synthesis, buthionine sulfoximine, or by the precursor of cysteine, O-acetylse

239 Iodination of aryls with N-iodo sulfoximines, oxidation, and conversion to N-SCF(3) cong

240 catalyst supported by an electron-deficient sulfoximine predominantly promoted the sulfonimidate pro

241 eatment of HeLa cells with 2 mm l-buthionine sulfoximine promoted the formation of ox-HSF1 and blocke

242 Sulfoximines provide aza-analogues of sulfones, with pot

243 method may facilitate the preparation of NH-sulfoximines providing improved (global) deprotection st

244 The inhibitor L-methionine-S-sulfoximine rapidly inactivated purified M. tuberculosis

245 of pathogenic mycobacteria, L-methionine- S-sulfoximine rapidly inhibited extracellular glutamine sy

246 N-Alkyl sulfoximines react with arynes generated in situ under m

247 Treatment with l-buthionine-(S,R)-sulfoximine reduced glutathione content by 99% and preve

248 glutathione by pretreatment with buthionine sulfoximine rendered cells more susceptible to G2/M arre

249 Glutathione depletion by dl-buthionine-(S,R)-sulfoximine rendered hepatocytes susceptible to AEA-medi

250 A sulfoximine reported recently by Koizumi et al. as a com

251 N-Arylation of NH-sulfoximines represents an appealing approach to access

252 ggravated by N-acetylcysteine and buthionine sulfoximine, respectively.

253 s of sulfoxides and sulfones, sulfimides and sulfoximines, respectively, are important compounds in a

254 glutathione synthetase inhibitor buthionine sulfoximine resulted in more rapid injury by glucose dep

255 e GSH synthesis inhibitor, L-buthionine-(SR)-sulfoximine, resulted in a time-dependent depletion of G

256 artificial microRNA interference using l-Met sulfoximine selection-based gene transformation systems

257 The C-N coupling products, N-arylated sulfoximines, serve as ligands along with NH-sulfoximine

258 ar antioxidant, glutathione, with buthionine sulfoximine significantly increased B[a]P-mediated induc

259 Sulfonimidamides (SIAs) and sulfoximines (SOIs) have attracted attention due to thei

260 uous GSH infusion, treatment with buthionine sulfoximine starting day - 2 decreased sinusoidal endoth

261 pared, differing not only at the stereogenic sulfoximine stereocenter but also at the A-ring.

262 or the asymmetric synthesis of both of these sulfoximine substitution patterns.

263 DFT calculations reveal that both the NH-sulfoximine substrate and the N-aryl product can ligate

264 e of glutamine was inhibited by l-methionine sulfoximine, suggesting a role for pita in protecting gl

265 nd intracellular GSH depletion by buthionine sulfoximine, suggesting that GSH transport is active and

266 Chiral sulfinyl compounds, sulfoxides, sulfoximines, sulfinamides, and other derivatives, play

267 or the rapid asymmetric synthesis of over 70 sulfoximines, sulfonimidoyl fluorides and sulfonimidamid

268 rstanding of decomposition-like reactions of sulfoximines thereby enabling a more focussed search and

269 Considering the outstanding properties of sulfoximines, this versatile functional group has advanc

270 sulfoximines, serve as ligands along with NH-sulfoximine to bind to the copper species, generating th

271 r treatment of cells with L-buthionine-(S,R)-sulfoximine to deplete glutathione, selenoprotein H-over

272 upling of bicyclo[1.1.1]pentyl moieties with sulfoximines to achieve a synergistic bioisosteric desig

273 rdingly, glutathione depletion by buthionine sulfoximine together with restoration of p53 activity re

274 eover, in contrast to AA, l-buthionine-(S,R)-sulfoximine toxicity is not prevented by plasmid Nrf2 pr

275 ted cells from both glutamate and buthionine sulfoximine toxicity.

276 tics were studied in acivicin and buthionine sulfoximine-treated HLE-B3 cells in NaCl medium in the c

277 ncreases from approximately 7% in methionine sulfoximine-treated mice to approximately 500% in dexame

278 sickling in the sickle kidney: in buthionine-sulfoximine-treated sickle mice, red blood cell sickling

279 Buthionine sulfoximine treatment resulted in a 24% reduction in can

280 y enhanced after GSH depletion by buthionine sulfoximine treatment.

281 depleting the glutathione pool by buthionine sulfoximine treatment.

282 substituted sulfilimine to the corresponding sulfoximine, treatment with trifluoracetic acid in an ap

283 N-allyl-, and N-benzyl-substituted S-alkenyl sulfoximines under appropriate conditions results in the

284 The N-aroyl sulfoximine undergoes annulation with diphenylacetylene,

285 ast, depletion of GSH by L-buthionine (S, R)-sulfoximine up-regulated the above described signaling c

286 emperatures during N-arylation of the simple sulfoximine used in this study.

287 cally relevant N-alpha,beta-unsaturated acyl sulfoximines via phosphine-catalyzed C-C bond activation

288 mental drugs, i.e., auranofin and buthionine sulfoximine, was able to reduce the viral reservoir, eli

289 Although these sulfoximines were not active transcriptionally and were

290 A wide range of structurally different NH-sulfoximines were prepared and reacted with N-fluorobenz

291 activation; whereas TNFalpha or l-buthionine sulfoximine, which depletes GSH, further enhanced it.

292 less than 15% of basal levels) by buthionine sulfoximine, which does not directly modify Keap1, is al

293 readily converted to an N-acyl and to a free sulfoximine, which represent important motifs in medicin

294 transfer is developed for the preparation of sulfoximines, which are emerging as valuable motifs for

295 n decarboxylation to the S-methyl N-pivaloyl sulfoximine, while aqueous HCl resulted in both decarbox

296 Cyclizations of NH-S-(2-hydroxyaryl)sulfoximines with 1,1'-carbonyldiimidazol (CDI) give unp

297 An efficient kinetic resolution of sulfoximines with enals was realized using chiral N-hete

298 , metal-free, and scalable transformation of sulfoximines with N-fluorobenzenesulfonamide is presente

299 Treatment of NH-sulfoximines with pseudocyclic benziodoxole triflate res

300 filimines were oxidized to the corresponding sulfoximines with subsequent reductive cleavage affordin